The World Health Organization’s (WHO) first-ever Investment Round reached a pivotal milestone at the G20 Leaders’ Summit in Rio de Janeiro. Chaired by Brazilian President H.E. Luiz Inácio Lula da Silva, the event saw heads of state and government voice…
CVS Health® (NYSE: CVS) announced the addition of four new members to its Board of Directors: Leslie Norwalk, Larry Robbins, Guy Sansone, and Doug Shulman. These appointments follow collaborative discussions with Glenview Capital Management. “Our discussions with Glenview have reinforced…
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a biopharmaceutical company focused on genetic diseases, has announced positive 18-month results from the Phase 2 PROPEL 2 trial evaluating infigratinib as a treatment for children with achondroplasia. The findings, published today in the New…
Equillium Reports Third Quarter 2024 Financial Results and Provides Corporate and Clinical Updates Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced…
AstraZeneca today announced a $3.5 billion investment in the United States to expand the company’s research and manufacturing footprint by the end of 2026. This includes $2 billion in new investments creating more than 1,000 new high-skilled jobs that will…
TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development TRex Bio, Inc. (“TRexBio”), a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, today announced the close of an oversubscribed $84…
Reverb Therapeutics, a leader harnessing the body’s immune system and cytokine signaling to treat life-threatening diseases, announced it has launched a collaboration with Royalmount Laboratories, based in Montreal, as Reverb works towards lead selection and pre-IND enabling work on its…
Baxter International Inc. (NYSE: BAX), a global leader in medical technology, today announced its financial results for the third quarter of 2024. “Baxter achieved strong performance in Q3 2024 as we continue to execute on our strategic transformation,” said José…
Royalty Pharma plc (Nasdaq: RPRX) announced an agreement to acquire a synthetic royalty on U.S. sales of Geron Corporation’s (Nasdaq: GERN) RYTELO, with a $125 million upfront cash payment. Approved by the U.S. FDA in June 2024, RYTELO is a…
WuXi Biologics (“WuXi Bio”) (2269.HK), a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) services, has received an AAA rating from Morgan Stanley Capital International (MSCI) ESG Ratings for the second consecutive year. This prestigious recognition acknowledges the…
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company developing transformative gene-based medicines for serious diseases, has released its financial results for Q3 ending September 30, 2024. “We are making strong progress across our pipeline of in vivo and ex vivo CRISPR-based…
Royalty Pharma plc (Nasdaq: RPRX) and Syndax Pharmaceuticals (Nasdaq: SNDX) have announced a $350 million synthetic royalty funding agreement, tied to the U.S. net sales of Niktimvo (axatilimab-csfr). “We are thrilled to partner with Syndax, a forward-thinking oncology company with…